Sun Pharmaceutical Industries Limited (BOM:524715)
India flag India · Delayed Price · Currency is INR
1,989.35
-11.40 (-0.57%)
At close: Jul 31, 2026

BOM:524715 Income Statement

Millions INR. Fiscal year is Apr - Mar.
Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
599,105584,620525,784484,969438,857386,545
Revenue Growth
11.40%11.19%8.42%10.51%13.53%15.39%
Cost of Revenue
126,270124,786115,585114,422113,187108,761
Gross Profit
472,835459,834410,200370,547325,670277,784
Selling, General & Admin
119,438115,183100,50995,02583,54973,544
Other Operating Expenses
185,671179,157157,883144,755123,779101,331
Operating Expenses
334,870323,718284,145265,345232,613196,223
Operating Income
137,965136,116126,055105,20293,05881,560
Interest Expense
-3,638-3,389-2,314-2,385-1,720-1,274
Interest & Investment Income
9,7449,74412,97011,2625,3107,687
Earnings From Equity Investments
-556.9-558.7-153.5-384.1-479-165.4
Currency Exchange Gain (Loss)
11,33112,4021,855361.3-1,2611,540
Other Non Operating Income (Expenses)
3,435843.7620.6546.7756.5735.9
EBT Excluding Unusual Items
158,281155,158139,034114,60395,66490,084
Merger & Restructuring Charges
-1,670--3,617-739.5-643.9-563.5
Gain (Loss) on Sale of Investments
8,6368,6365,117921.9-240.37.7
Gain (Loss) on Sale of Assets
-64.5-64.5-164-99.775.4347.5
Asset Writedown
-1,708-1,708-71.3-1,564-312.5-2,179
Legal Settlements
-693.8-693.8-58.2---1,563
Other Unusual Items
-3,057-10,866-3,104-2,712-1,071-41,657
Pretax Income
159,892150,630137,368110,49593,60544,648
Income Tax Expense
38,72235,54427,72014,3958,47610,755
Earnings From Continuing Operations
121,170115,087109,64896,10085,12933,893
Minority Interest in Earnings
-214.3-292.3-357.1-336.5-393.6-1,166
Net Income
120,956114,794109,29095,76484,73632,727
Net Income to Common
120,956114,794109,29095,76484,73632,727
Net Income Growth
16.62%5.04%14.12%13.01%158.92%12.70%
Shares Outstanding (Basic)
2,3982,3992,3992,3992,3992,399
Shares Outstanding (Diluted)
2,3982,3992,3992,3992,3992,399
Shares Change
-0.02%-----
EPS (Basic)
50.4447.8445.5539.9135.3213.64
EPS (Diluted)
50.4047.8045.5539.9035.3013.60
EPS Growth
16.54%4.94%14.16%13.03%159.56%12.40%

Additional Metrics

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Free Cash Flow
-88,098119,43599,33228,73874,895
Free Cash Flow Per Share
-36.7249.7841.4011.9831.21
Dividend Per Share
-16.00016.00013.50011.50010.000
Dividend Growth
-0%18.52%17.39%15.00%33.33%
Gross Margin
78.92%78.66%78.02%76.41%74.21%71.86%
Operating Margin
23.03%23.28%23.97%21.69%21.20%21.10%
Profit Margin
20.19%19.64%20.79%19.75%19.31%8.47%
Free Cash Flow Margin
-15.07%22.72%20.48%6.55%19.38%
EBITDA
165,832163,135149,679128,760116,513101,536
EBITDA Margin
27.68%27.90%28.47%26.55%26.55%26.27%
D&A For EBITDA
27,86727,01923,62523,55923,45619,975
EBIT
137,965136,116126,055105,20293,05881,560
EBIT Margin
23.03%23.28%23.97%21.69%21.20%21.10%
Effective Tax Rate
24.22%23.60%20.18%13.03%9.05%24.09%
Revenue as Reported
621,414604,338545,435498,510445,202395,760